Altre lingue Barinthus Biotherapeutics plc

Azioni

BRNS

US91864C1071

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 25/04/2024			Variaz. 5gg	Var. 1 gen.
2,429 ^USD	-3,23%		-10,37%	-34,18%

18/04	BarinthuBarinthus Biotherapeutics plc annuncia i dati topline dello studio di Fase 1b/2 APOLLO di VTP-200 nelle infezioni persistenti da Papillomavirus umano (HPV) ad alto rischio	CI
20/03	Barinthus Biotherapeutics plc riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Barinthus Cervical Lesions Treatment Study Meets Primary Objective -- Shares Rise After Hours	18/04
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections	18/04
BarinthuBarinthus Biotherapeutics plc Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus Infections	18/04
ADRs Advance; Connect Biopharma Climbs 19%	05/04
ADRs End Higher, Aesthetic Medical International Holdings Group Ltd. Climbs 35.5%	03/04
Barinthus Biotherapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments	20/03
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones	05/01
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones	05/01
New partnership aims to advance vaccine against MERS coronavirus	21/12
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD	09/11
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD	09/11
Barinthus Biotherapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments	09/11
CanSino Biologics Enrolls First Case in Recombinant Zoster Vaccine Trial in Canada	09/11
Barinthus Biotherapeutics plc(NasdaqGM:BRNS) added to NASDAQ Composite Index	08/11
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer	06/11
Vaccitech plc(NasdaqGM:VACC) dropped from NASDAQ Composite Index	06/11
ADRs End Higher; TC Biopharm PLC Climbs 19%	30/10/23
Are we globally prepared for the next pandemic?	30/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Barinthus Biotherapeutics plc

Azioni

BRNS

US91864C1071

Altre lingue

Filtri